Critical to improve survival and outcomes for Pseudomyxoma peritonei – Manchester Cancer Research Centre
Manchester Cancer Research Centre shared a post on LinkedIn:
“Pseudomyxoma peritonei (PMP) is a rare appendix tumour with an estimated incidence of 1-2 cases per million. Because of its rarity, there have been no new developments in treatments for 30 years making work in this field critical to improve survival and outcomes.
In Manchester, The Christie is one of two centres in the UK treating PMP, putting us at the forefront of the treatment developments for the disease.
In 2019, we established an international multicentre at five institutions in the UK, Italy and Spain supported by a Cancer Research UK Accelerator to study PMP.
Five years on, we’ve collected more than 400 samples, classified genetic mutations in PMP, and identified new therapeutic approaches for PMP.
Read more in our impact case study.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023